Partner Aaron Tantleff was quoted in the Digiday article, ‘We’re not going to play around’: Ad industry grapples with California’s ambiguous privacy law,” about how many businesses are still grappling with what the California Consumer Privacy Act requires of their advertising practices.
While the California attorney general’s office is expected to clarify enforcement rules, many companies are taking conservative initial approaches to ensure they are compliant with the law by pulling back on targeted advertising and adopting limits on what they do with the data they receive from other companies.
“Digital advertisers use a variety of types of information that may be personal and is exchanged with other companies in order to fulfill their purpose or their services. Whether that meets the definition of sale under CCPA is questionable in some cases,” said Tantleff.
While the California attorney general’s office is expected to clarify enforcement rules, many companies are taking conservative initial approaches to ensure they are compliant with the law by pulling back on targeted advertising and adopting limits on what they do with the data they receive from other companies.
“Digital advertisers use a variety of types of information that may be personal and is exchanged with other companies in order to fulfill their purpose or their services. Whether that meets the definition of sale under CCPA is questionable in some cases,” said Tantleff.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”